Global Alpha Capital Management Ltd. Invests $1.52 Million in Certara, Inc. $CERT

Global Alpha Capital Management Ltd. bought a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 4th quarter, HoldingsChannel.com reports. The fund bought 172,700 shares of the company’s stock, valued at approximately $1,521,000.

A number of other large investors have also modified their holdings of CERT. Northwestern Mutual Wealth Management Co. grew its stake in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after purchasing an additional 2,870 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after acquiring an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Certara during the second quarter worth $83,000. Finally, Curated Wealth Partners LLC acquired a new stake in Certara in the fourth quarter valued at $89,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Shares of Certara stock opened at $5.37 on Friday. The firm’s fifty day simple moving average is $5.63 and its 200-day simple moving average is $7.29. The stock has a market capitalization of $835.41 million, a price-to-earnings ratio of -53.70 and a beta of 1.49. Certara, Inc. has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the prior year, the company earned $0.14 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities analysts forecast that Certara, Inc. will post 0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CERT shares. Leerink Partners reiterated an “outperform” rating and issued a $10.00 price objective on shares of Certara in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Morgan Stanley reduced their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Craig Hallum decreased their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Finally, Barclays dropped their price objective on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.